Loading…
RxSight, Inc. is projected to rise to $5.57 by 2027, a +13% move from its current price of $4.95. RXST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.78 | $4.95 | $5.13 | +0.04% |
| Jul 14 | $4.71 | $4.95 | $5.21 | +0.07% |
| Jul 15 | $4.66 | $4.96 | $5.27 | +0.11% |
| Jul 16 | $4.61 | $4.96 | $5.33 | +0.14% |
| Jul 17 | $4.58 | $4.96 | $5.37 | +0.18% |
| Jul 18 | $4.54 | $4.96 | $5.42 | +0.21% |
| Jul 19 | $4.51 | $4.96 | $5.46 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.51 | $4.96 | $5.46 | +0.25% |
| Week 2 | $4.35 | $4.97 | $5.69 | +0.49% |
| Week 3 | $4.23 | $4.99 | $5.88 | +0.74% |
| Week 4 | $4.14 | $5.00 | $6.04 | +0.99% |
| Week 5 | $4.05 | $5.01 | $6.19 | +1.23% |
| Week 6 | $3.98 | $5.02 | $6.34 | +1.48% |
| Week 7 | $3.92 | $5.04 | $6.47 | +1.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
RxSight, Inc. is a commercial-stage medical technology company that researches, develops, manufactures, and sells light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers the RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery, including the RxSight Light Adjustable Lens (LAL) and a light delivery device that modifies the lens in a programmed pattern to achieve the desired vision.
The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RxSight, Inc. trades under the symbol RXST and has a current price of $5.31 with a market cap of $219.82M, ranking 3757 by market capitalization. The stock’s near-term technical landscape shows a trading range consistent with a cautious stance, with a 30-day range between $4.30 and $6.55.
The two commonly watched moving averages are SMA50 at $5.98 and SMA200 at $8.30, with a nearby resistance at $6.35 and support at $4.59. The stock’s annualized volatility is 60%. The current price level sits near a neutral short-term footing given the 50 RSI.
The forecast implies a path that begins at a similar level in 2026 and builds toward larger gains later in the horizon, with a long-run average price rising to multiple higher targets.
A major floor 18.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 13.5% above — a clean break opens room to run.
A major ceiling 60.2% above — clearing it would confirm fresh momentum.
Key RXST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RXST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.32 | Sell | $5.19 | Sell |
| MA 10 | $5.27 | Sell | $5.21 | Sell |
| MA 20 | $5.08 | Sell | $5.21 | Sell |
| MA 50 | $5.53 | Sell | $5.60 | Sell |
| MA 100 | $6.44 | Sell | $6.46 | Sell |
| MA 200 | $8.08 | Sell | $8.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.77 | Neutral |
| Stoch RSI (14) | 14.83 | Buy |
| CCI (20) | -32.01 | Neutral |
| Williams %R (14) | -83.75 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -5.17 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 16.25 | Buy |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | 0.14 | Buy |
| Ultimate (7,14,28) | 53.00 | Neutral |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 5.20 | Sell |
| ADX (14) | 15.80 | Neutral |
| ATR (14) | 0.19 | Info |
The 30-day picture shows a neutral stance with RSI at 50. The SMA50 at $5.98 sits below the SMA200 at $8.30, indicating that a longer-term upward move would need to overcome resistance near $8.30. The near-term support is reported at $4.59, while resistance sits at $6.35, framing a range roughly between $4.30 and $6.55 over the last 30 days.
These levels suggest a cautious posture as traders assess momentum and potential breakouts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.59 | $4.95 | $6.63 | 0% | Neutral | |
| $4.31 | $5.57 | $7.70 | +13% | Neutral | |
| $4.05 | $5.44 | $7.87 | +10% | Neutral | |
| $3.69 | $5.11 | $7.67 | +3% | Neutral | |
| $3.55 | $5.06 | $7.83 | +2% | Neutral | |
| $3.79 | $5.54 | $8.80 | +12% | Neutral | |
| $4.72 | $7.07 | $11.49 | +43% | Bullish | |
| $4.67 | $7.16 | $11.88 | +45% | Bullish | |
| $4.15 | $6.52 | $11.02 | +32% | Bullish | |
| $4.42 | $7.08 | $12.19 | +43% | Bullish | |
| $5.35 | $9.46 | $17.54 | +91% | Bullish | |
| $8.28 | $17.43 | $35.97 | +252% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.59 | $4.95 | $5.99 | +0.00% |
| August 2026 | $4.34 | $5.16 | $6.34 | +4.24% |
| September 2026 | $4.25 | $5.11 | $6.37 | -0.96% |
| October 2026 | $4.05 | $4.90 | $6.18 | -4.11% |
| November 2026 | $4.08 | $4.97 | $6.33 | +1.42% |
| December 2026 | $4.20 | $5.16 | $6.63 | +3.73% |
Click any year to see its month-by-month RXST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RXST is projected to trade between $4.59 and $6.63, averaging $4.95 — a potential gain of 0% from today's $4.95. Price action looks broadly range-bound.
RxSight, Inc.'s 2027 outlook centres on $5.57, within a $4.31 to $7.70 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, RXST could reach as high as $7.87, with a base case around $5.44 and support toward $4.05 — roughly +10% from $4.95. Price action looks broadly range-bound.
Expect RXST to range from $3.69 to $7.67 through 2029. The $5.11 average target implies a +3% move from current prices. That is -6% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The RXST price prediction for 2030 points to an average of $5.06 (low $3.55, high $7.83) — a potential gain of +2% on today's $4.95. Price action looks broadly range-bound.
In 2031, RXST is projected to trade between $3.79 and $8.80, averaging $5.54 — a potential gain of +12% from today's $4.95. That is up +10% on the projected 2030 average. A consolidation phase looks the most probable path here.
RxSight, Inc.'s 2032 outlook centres on $7.07, within a $4.72 to $11.49 range. That is up +28% on the projected 2031 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2033, RXST could reach as high as $11.88, with a base case around $7.16 and support toward $4.67 — roughly +45% from $4.95. Buyers look set to stay in control over this stretch.
Expect RXST to range from $4.15 to $11.02 through 2034. The $6.52 average target implies a +32% move from current prices. That is -9% versus the projected 2033 average. Momentum favours further upside here.
The RXST price prediction for 2035 points to an average of $7.08 (low $4.42, high $12.19) — a potential gain of +43% on today's $4.95. Buyers look set to stay in control over this stretch.
In 2040, RXST is projected to trade between $5.35 and $17.54, averaging $9.46 — a potential gain of +91% from today's $4.95. That is up +34% on the projected 2035 average. Momentum favours further upside here.
RxSight, Inc.'s 2050 outlook centres on $17.43, within a $8.28 to $35.97 range. That is up +84% on the projected 2040 average. That marks a +252% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RXST today (≈ 202.020202 RXST) could be worth
$3,521.61
+$2,521.61 (+252%) by 2050 · US Dollar
Based on the average projected RXST price of $17.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RXSTwould be worth at today's price.
$1,000 invested in RXST on Jul 10, 2025 (≈ 118.203309 RXST) would be worth
$585.11
-$414.89 (-41.5%) today · 0.59× · US Dollar
Based on a RXST entry price of $8.46 vs. today's $4.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.61 | $882.35 | -11.8% |
| 1 month ago | $4.6 | $1,076.09 | +7.6% |
| 3 months ago | $6.83 | $724.74 | -27.5% |
| 6 months ago | $10.09 | $490.58 | -50.9% |
| 1 year ago | $8.46 | $585.11 | -41.5% |
| All time (4.9y) ago | $16 | $309.38 | -69.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RXST forecast.
Our base-case forecast reaches $9.90 around 2050.
Implied market cap at $9.90: $409.83M
The multi-year forecast presents a progression from neutral in the near term to bullish later in the horizon. For 2026 the expected average price is $5.31 with a min of $4.59 and a max of $7.04 and ROI of 0%. In 2027 the average is $5.88 (min $4.60, max $7.99) with ROI 10.6%.
2028 shows an average of $5.96 (min $4.51, max $8.45) and ROI 12.3%. 2029’s average is $5.45 (min $4.02, max $7.99) with ROI 2.7%, and 2030’s average is $5.54 (min $3.98, max $8.34) with ROI 4.3%. Beginning in 2031 the outlook turns more decisively bullish: 2031 avg $6.40 (min $4.50, max $9.87) ROI 20.6%; 2032 avg $7.56 (min $5.21, max $11.90) ROI 42.4%; 2033 avg $7.66 (min $5.18, max $12.30) ROI 44.3%; 2034 avg $7.35 (min $4.87, max $12.01) ROI 38.4%; 2035 avg $7.71 (min $5.02, max $12.80) ROI 45.2%.
The horizon extends to 2040 with avg $10.54 (min $6.32, max $18.75) ROI 98.5% and to 2050 with avg $19.17 (min $9.94, max $37.65) ROI 261.1%. These figures reflect a shift toward bullish sentiment in the later years and show meaningful upside potential, while noting that these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows min $3.98, avg $5.54, max $8.34, ROI 4.3%, sentiment NEUTRAL.
Near term is NEUTRAL through 2029, with bullish momentum developing in 2031 and beyond. The 2031–2050 forecasts show higher Avg prices and ROIs (e.g., 2031 ROI 20.6%, 2050 ROI 261.1%), but these are estimates and not guarantees.
Yes. The 2030 forecast lists a max of $8.34 and an average of $5.54, with a min of $3.98.
Current price is $5.31 and market cap is $219.82M.
2031 avg $6.40 (ROI 20.6%), 2032 avg $7.56 (ROI 42.4%), 2033 avg $7.66 (ROI 44.3%), 2034 avg $7.35 (ROI 38.4%), 2035 avg $7.71 (ROI 45.2%).
RxSight, Inc. Community Discussion
0Share your RxSight, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.